Daraxonrasib Doubles Stage 4 Pancreatic Cancer Survival as FDA Reviews July 22 Application
Updated
Updated · KSL.com · Aug 11
Daraxonrasib Doubles Stage 4 Pancreatic Cancer Survival as FDA Reviews July 22 Application
3 articles · Updated · KSL.com · Aug 11
Summary
13.2 months of median survival in trials, up from 6.7 months on chemotherapy, has put daraxonrasib on track for broader use in stage 4 pancreatic cancer.
July 22 marked the FDA filing for the KRAS-targeting pill, while Intermountain Health said nine approved patients are waiting for first shipments through an Expanded Access Program.
10 Intermountain hospitals in Utah, Colorado and Montana can provide the drug early, extending access beyond major cancer centers as doctors call it a meaningful advance rather than a cure.
67,000 Americans are diagnosed with pancreatic cancer each year and about 52,000 die, underscoring why oncologists view the first therapy to directly target the common KRAS mutation as a major step.
Could a daily pill targeting a once-undruggable mutation finally rewrite the grim reality of advanced pancreatic cancer?
With survival times doubled, will this experimental cancer drug reach desperate patients before the FDA makes its final ruling?
Beyond the hype of extending life by six months, what hidden risks lurk within this revolutionary new targeted therapy?
Doubling Survival in Pancreatic Cancer: The Daraxonrasib Revolution and the Rise of Multi-Selective RAS(ON) Inhibitors
Overview
Daraxonrasib, a groundbreaking oral RAS(ON) inhibitor, has nearly doubled survival for patients with metastatic pancreatic cancer in the pivotal RASolute 302 trial, leading to rapid regulatory progress in the US, Europe, and Switzerland. Its unique tri-complex mechanism blocks tumor growth by targeting the active RAS protein, overcoming the failures of earlier drugs. This success has driven new clinical trials for first-line and adjuvant treatment, expanded access programs, and FDA Breakthrough Therapy Designation for lung cancer. As the oncology field shifts toward targeted therapies, daraxonrasib’s high cost and limited global access remain major challenges, especially outside the US.